Aplastic anemia
Pathology · Topic 17
Source: NMC CBME Curriculum 2024 · Volume I · Pathology · Topic 17 · combined PDF page 192
Practice questions
- Which combination best captures the defining disease pattern of aplastic anemia described in the supplied guidelines?
- A patient has pancytopenia and a hypocellular marrow. Which diagnostic conclusion is most appropriate based on these findings alone?
- A marrow-failure workup must distinguish aplastic anemia from hypocellular MDS and hypocellular AML. Which approach is supported by the cited diagnostic recommendations?
- Which set contains only diagnostic entities specifically identified as mimics or differential diagnoses of aplastic anemia in the supplied diagnostic recommendations?
- In the standardized evaluation of suspected aplastic anemia versus hypocellular MDS or AML, which statement about cytogenetics is best supported?
- A clinician is evaluating a hypocellular marrow in which aplastic anemia and hypocellular AML are both under consideration. Which ancillary modality is explicitly included in the cited standardized diagnostic recommendations?
- Which statement about flow cytometry in the differential diagnosis of aplastic anemia, hypocellular MDS, and hypocellular AML is supported by the supplied literature?
- According to the 2024 pediatric guideline, what is the approximate annual incidence of aplastic anemia in the Western world?
- How does the reported incidence of aplastic anemia in East Asia compare with that in the Western world in the 2024 pediatric guideline?
- For a child with severe aplastic anemia and an available matched sibling donor, which treatment is identified as first-line in the 2024 pediatric guideline?
- A child with severe aplastic anemia has no matched sibling donor. Which group of alternatives is listed in the 2024 pediatric guideline?
- An adult with severe aplastic anemia lacks a matched related donor. Which donor strategy is supported by the 2024 ASTCT guideline?
- Which statement best reflects the 2024 ASTCT position on using age 40 as an absolute cutoff for upfront transplantation in adults with severe aplastic anemia?
- Which graft source does the 2024 ASTCT guideline preferentially recommend for transplantation in severe aplastic anemia?
- When antithymocyte globulin is used in transplant conditioning for severe aplastic anemia, which preparation does the ASTCT guideline prefer?
- Which conditioning approach does the ASTCT guideline prefer for patients at high risk of graft failure or receiving a matched unrelated or haploidentical donor transplant?
- For a matched related or matched unrelated donor recipient with severe aplastic anemia, which graft-versus-host disease prophylaxis options are endorsed by the ASTCT guideline?
- A patient receiving care for severe aplastic anemia has neutropenia. Which supportive measure is specifically recommended in the 2026 ASH guideline for patients with neutropenia?
- Which agent does the 2026 ASH guideline recommend adding to immunosuppressive regimens for severe acquired aplastic anemia?
- A patient with severe aplastic anemia has failed immunosuppressive therapy. Which role for hematopoietic cell transplantation is stated in the 2026 ASH guideline?
- Which statement best characterizes the role of allogeneic hematopoietic cell transplantation in severe aplastic anemia in the supplied guidelines?
- According to the 2026 ASH guideline, which group is specifically highlighted for prioritizing hematopoietic cell transplantation?
- In the SFGM-TC consensus specifically addressing acquired aplastic anemia management in emerging-country settings, which first-line transplant recommendation is made for patients younger than 40 years with severe or very severe disease?
- In the SFGM-TC consensus for emerging-country settings, what treatment is recommended for patients older than 40 years or those lacking an HLA-identical donor?
- A practice question asks whether the SFGM-TC recommendation for patients younger than 40 years with severe aplastic anemia can be generalized as a universal international age rule. Which answer is most accurate?
- Which statement accurately reflects the supplied pediatric guideline when a matched sibling donor is unavailable for a child with severe aplastic anemia?
- Which statement correctly distinguishes the supplied guideline recommendations about ATG in transplantation from the ASH recommendation about immunosuppressive regimens?
- Which statement best summarizes the certainty of evidence described in the 2026 ASH severe aplastic anemia guideline abstract?
- Which paired finding and diagnostic implication is most defensible when a bone marrow examination is performed for suspected aplastic anemia?